renal cell carcinoma

• 

Statins improve the effectiveness of nivolumab for advanced kidney cancer

By Sharon Deveson Kell|2022-07-11T08:36:30+00:0011 Jul 2022|Drug treatments|

Statins are a group of medicines that can help lower [...]

Read More

Comments Off on Statins improve the effectiveness of nivolumab for advanced kidney cancer

• 

Incidence and risk of unplanned conversion from partial to radical nephrectomy

By Sharon Deveson Kell|2022-07-11T08:10:30+00:0011 Jul 2022|Surgery|

Partial nephrectomy, where the part of the kidney containing the [...]

Read More

Comments Off on Incidence and risk of unplanned conversion from partial to radical nephrectomy

• 

Papillary type I vs type II renal cell carcinoma

By Sharon Deveson Kell|2022-06-28T08:44:46+00:0028 Jun 2022|Subtypes of RCC|

Papillary renal cell carcinoma (pRCC) is the second most common [...]

Read More

Comments Off on Papillary type I vs type II renal cell carcinoma

• 

AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?

By Sharon Deveson Kell|2022-06-28T08:24:52+00:0028 Jun 2022|Drug treatments|

The 2022 American Urological Association (AUA) Annual Meeting included a [...]

Read More

Comments Off on AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?

• 

ASCO 2022: Sequencing of kidney cancer medicines

By Sharon Deveson Kell|2022-06-21T14:19:37+00:0021 Jun 2022|Drug treatments|

During the American Society of Clinical Oncology (ASCO)  Annual Meeting [...]

Read More

Comments Off on ASCO 2022: Sequencing of kidney cancer medicines

• 

Sequencing of treatments for advanced/metastatic kidney cancer

By Sharon Deveson Kell|2022-06-14T08:25:47+00:0014 Jun 2022|Drug treatments|

During the American Society of Clinical Oncology Annual Meeting earlier [...]

Read More

Comments Off on Sequencing of treatments for advanced/metastatic kidney cancer

• 

Three years follow-up data from the belzutifan study for pre-treated metastatic kidney cancer

By Sharon Deveson Kell|2022-06-08T10:51:54+00:008 Jun 2022|Drug treatments|

Studies looking at the genes of people with kidney cancer [...]

Read More

Comments Off on Three years follow-up data from the belzutifan study for pre-treated metastatic kidney cancer

• 

Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?

By Sharon Deveson Kell|2022-06-08T10:36:43+00:008 Jun 2022|Drug treatments|

Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]

Read More

Comments Off on Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?

• 

Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

By Sharon Deveson Kell|2022-06-08T10:28:09+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?

• 

Can adjuvant everolimus prevent recurrence following surgery?

By Sharon Deveson Kell|2022-06-08T07:53:18+00:008 Jun 2022|Drug treatments|

At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]

Read More

Comments Off on Can adjuvant everolimus prevent recurrence following surgery?